A Delaware federal judge has extinguished Mallinckrodt Pharmaceuticals’ patent infringement suit against industrial gases company Praxair Inc., striking five of the Irish drugmaker’s patents for its INOMAX respiratory treatment system as invalid and ruling that Praxair had not infringed on five more.
Mallinckrodt had sued in 2015 to protect its patents for INOMAX, the company’s second best-selling product, which accounts for 15 percent of Mallinckrodt’s total revenue and brings in $500 million in annual sales. According to court documents, the patents related to an inhaled nitric oxide and the devices were used to administer it to newborns and children with breathing disorders.
